Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β4 in medulloblastoma

Naeem, Ayesha; Knoer, Grace; Avantaggiati, Maria Laura; Rodriguez, Olga; Albanese, Chris

doi:10.1016/j.intimp.2023.109785

Cited by 2 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our recent findings highlight the atypical involvement of PI3K-Akt kinases and p53 in triggering both cell death and resistance, facilitated by the FDA-approved thymosin beta 4 (Tβ4) drug in medulloblastoma (MB) cells [ 77 , 78 ]. The success of these groundbreaking studies, unraveling Tβ4’s influence on MB and GB cells, sets the stage for future investigations into the intricate roles of p53 and PI3K/AKT in cancer cells characterized by elevated p53 levels [ 79 ]. This research is poised to guide the development of methodologies assessing p53 levels in patient specimens and potentially pave the way for the clinical application of Tβ4.…”

Section: Molecular Targeted Therapymentioning

confidence: 99%

Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy

Zafar,

Khan,

Abu

et al. 2024

Mol Biol Rep

Self Cite

View full text Add to dashboard Cite

Despite the availability of technological advances in traditional anti-cancer therapies, there is a need for more precise and targeted cancer treatment strategies. The wide-ranging shortfalls of conventional anticancer therapies such as systematic toxicity, compromised life quality, and limited to severe side effects are major areas of concern of conventional cancer treatment approaches. Owing to the expansion of knowledge and technological advancements in the field of cancer biology, more innovative and safe anti-cancerous approaches such as immune therapy, gene therapy and targeted therapy are rapidly evolving with the aim to address the limitations of conventional therapies. The concept of immunotherapy began with the capability of coley toxins to stimulate toll-like receptors of immune cells to provoke an immune response against cancers. With an in-depth understating of the molecular mechanisms of carcinogenesis and their relationship to disease prognosis, molecular targeted therapy approaches, that inhibit or stimulate specific cancer-promoting or cancer-inhibitory molecules respectively, have offered promising outcomes. In this review, we evaluate the achievement and challenges of these technically advanced therapies with the aim of presenting the overall progress and perspective of each approach.

show abstract

Section: Molecular Targeted Therapymentioning

confidence: 99%